Tyrosine Kinase Inhibitors: Renal and Prostate Cancer - ESMO 2023

By. Joaquim Bellmunt, MD, PhD

Date. 11/17/2023

At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Joaquim Bellmunt, MD, PhD, from Harvard Medical School in Boston, MA, shared insights on advancements in renal cancer during a dedicated session. Discussing first-line treatment options, Dr. Bellmunt highlighted the four established choices, including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. In an interview, he touched upon the critical analysis of which patients are best suited for each treatment strategy.

During the session, Dr. Bellmunt delved into the Phase III CONTACT-02 trial (NCT04446117) focusing on prostate cancer. The trial evaluated the efficacy of a combination therapy involving immunotherapy (atezolizumab) and a tyrosine kinase inhibitor (cabozantinib). Notably, this approach demonstrated results, representing a development in the field of prostate cancer treatment. Dr. Bellmunt emphasized that these findings, although preliminary and currently available only through press release, indicate the potential for a new treatment option in metastatic castration-resistant prostate cancer.

This session provided a platform to discuss and analyze the evolving landscape of cancer treatment, specifically in renal and prostate cancers, shedding light on innovative strategies that may shape the future of patient care.

Tyrosine Kinase Inhibitors: Renal and Prostate Cancer - ESMO 2023

Joaquim Bellmunt, MD, PhD, discussed first-line options for renal cancer, emphasizing TKIs and immune checkpoint inhibitors. The Phase III CONTACT-02 trial explored a combination of atezolizumab and cabozantinib for prostate cancer, showing potential in metastatic cases.